Abbott Laboratories annual ebitda
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Abbott Laboratories EBITDA Growth & History (ABT)
Abbott Laboratories's calculated EBITDA was $11.17B for fiscal 2025.
View full Abbott Laboratories company overviewAbbott Laboratories annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.17B | $1.13B | +11.21% |
| 2024 | 2024-12-31 | $10.04B | $322.0M | +3.31% |
| 2023 | 2023-12-31 | $9.72B | −$1.91B | −16.41% |
| 2022 | 2022-12-31 | $11.63B | −$334.0M | −2.79% |
| 2021 | 2021-12-31 | $11.96B | $3.28B | +37.76% |
| 2020 | 2020-12-31 | $8.68B | $1.14B | +15.08% |
| 2019 | 2019-12-31 | $7.55B | $618.0M | +8.92% |
| 2018 | 2018-12-31 | $6.93B | $2.34B | +51.10% |
| 2017 | 2017-12-31 | $4.58B | $206.0M | +4.70% |
| 2016 | 2016-12-31 | $4.38B | $40.0M | +0.92% |
| 2015 | 2015-12-31 | $4.34B | $192.0M | +4.63% |
| 2014 | 2014-12-31 | $4.15B | $295.0M | +7.66% |
| 2013 | 2013-12-31 | $3.85B | −$290.0M | −7.00% |
| 2012 | 2012-12-31 | $4.14B | −$531.0M | −11.36% |
| 2011 | 2011-12-31 | $4.67B | −$4.04B | −46.36% |
| 2010 | 2010-12-31 | $8.71B | $386.6M | +4.64% |
| 2009 | 2009-12-31 | $8.33B | $792.6M | +10.52% |
| 2008 | 2008-12-31 | $7.53B | $1.10B | +17.09% |
| 2007 | 2007-12-31 | $6.43B | — | — |
Abbott Laboratories quarterly ebitda
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $2.15B | −$301.0M | −12.29% |
| Q4 2025 | 2025-12-31 | $3.04B | $325.0M | +11.96% |
| Q3 2025 | 2025-09-30 | $2.85B | $188.0M | +7.07% |
| Q2 2025 | 2025-06-30 | $2.83B | $355.0M | +14.35% |
| Q1 2025 | 2025-03-31 | $2.45B | $258.0M | +11.78% |
| Q4 2024 | 2024-12-31 | $2.72B | $125.0M | +4.82% |
| Q3 2024 | 2024-09-30 | $2.66B | $189.0M | +7.65% |
| Q2 2024 | 2024-06-30 | $2.47B | $132.0M | +5.64% |
| Q1 2024 | 2024-03-31 | $2.19B | −$124.0M | −5.36% |
| Q4 2023 | 2023-12-31 | $2.59B | $482.0M | +22.83% |
| Q3 2023 | 2023-09-30 | $2.47B | −$114.0M | −4.41% |
| Q2 2023 | 2023-06-30 | $2.34B | −$856.0M | −26.77% |
| Q1 2023 | 2023-03-31 | $2.31B | −$1.42B | −38.02% |
| Q4 2022 | 2022-12-31 | $2.11B | −$1.15B | −35.27% |
| Q3 2022 | 2022-09-30 | $2.58B | −$808.0M | −23.81% |
| Q2 2022 | 2022-06-30 | $3.20B | $932.0M | +41.13% |
| Q1 2022 | 2022-03-31 | $3.73B | $692.0M | +22.74% |
| Q4 2021 | 2021-12-31 | $3.26B | −$37.0M | −1.12% |
| Q3 2021 | 2021-09-30 | $3.39B | $1.09B | +47.33% |
| Q2 2021 | 2021-06-30 | $2.27B | $769.0M | +51.37% |
| Q1 2021 | 2021-03-31 | $3.04B | $1.46B | +91.87% |
| Q4 2020 | 2020-12-31 | $3.30B | $1.15B | +53.75% |
| Q3 2020 | 2020-09-30 | $2.30B | $351.0M | +17.98% |
| Q2 2020 | 2020-06-30 | $1.50B | −$460.0M | −23.51% |
| Q1 2020 | 2020-03-31 | $1.59B | $94.0M | +6.30% |
| Q4 2019 | 2019-12-31 | $2.15B | $217.0M | +11.26% |
| Q3 2019 | 2019-09-30 | $1.95B | $144.0M | +7.96% |
| Q2 2019 | 2019-06-30 | $1.96B | $225.0M | +12.99% |
| Q1 2019 | 2019-03-31 | $1.49B | $32.0M | +2.19% |
| Q4 2018 | 2018-12-31 | $1.93B | $434.0M | +29.05% |
| Q3 2018 | 2018-09-30 | $1.81B | $283.0M | +18.56% |
| Q2 2018 | 2018-06-30 | $1.73B | $698.0M | +67.50% |
| Q1 2018 | 2018-03-31 | $1.46B | $928.0M | +174.44% |
| Q4 2017 | 2017-12-31 | $1.49B | $386.0M | +34.84% |
| Q3 2017 | 2017-09-30 | $1.52B | $288.0M | +23.28% |
| Q2 2017 | 2017-06-30 | $1.03B | −$129.0M | −11.09% |
| Q1 2017 | 2017-03-31 | $532.0M | −$339.0M | −38.92% |
| Q4 2016 | 2016-12-31 | $1.11B | −$73.0M | −6.18% |
| Q3 2016 | 2016-09-30 | $1.24B | $141.0M | +12.86% |
| Q2 2016 | 2016-06-30 | $1.16B | $82.0M | +7.59% |
| Q1 2016 | 2016-03-31 | $871.0M | −$110.0M | −11.21% |
| Q4 2015 | 2015-12-31 | $1.18B | −$43.0M | −3.51% |
| Q3 2015 | 2015-09-30 | $1.10B | $13.0M | +1.20% |
| Q2 2015 | 2015-06-30 | $1.08B | $4.0M | +0.37% |
| Q1 2015 | 2015-03-31 | $981.0M | $218.0M | +28.57% |
| Q4 2014 | 2014-12-31 | $1.22B | $380.0M | +45.02% |
| Q3 2014 | 2014-09-30 | $1.08B | $174.0M | +19.14% |
| Q2 2014 | 2014-06-30 | $1.08B | $14.0M | +1.32% |
| Q1 2014 | 2014-03-31 | $763.0M | −$273.0M | −26.35% |
| Q4 2013 | 2013-12-31 | $844.0M | $279.8M | +49.60% |
| Q3 2013 | 2013-09-30 | $909.0M | −$160.7M | −15.03% |
| Q2 2013 | 2013-06-30 | $1.06B | −$192.6M | −15.34% |
| Q1 2013 | 2013-03-31 | $1.04B | −$216.5M | −17.28% |
| Q4 2012 | 2012-12-31 | $564.2M | $1.96B | — |
| Q3 2012 | 2012-09-30 | $1.07B | −$363.5M | −25.36% |
| Q2 2012 | 2012-06-30 | $1.26B | −$1.33B | −51.42% |
| Q1 2012 | 2012-03-31 | $1.25B | −$794.4M | −38.81% |
| Q4 2011 | 2011-12-31 | −$1.39B | −$3.93B | — |
| Q3 2011 | 2011-09-30 | $1.43B | −$424.9M | −22.87% |
| Q2 2011 | 2011-06-30 | $2.58B | $303.7M | +13.31% |
| Q1 2011 | 2011-03-31 | $2.05B | $13.8M | +0.68% |
| Q4 2010 | 2010-12-31 | $2.54B | $128.4M | +5.32% |
| Q3 2010 | 2010-09-30 | $1.86B | −$322.3M | −14.78% |
| Q2 2010 | 2010-06-30 | $2.28B | $72.3M | +3.28% |
| Q1 2010 | 2010-03-31 | $2.03B | $508.2M | +33.33% |
| Q4 2009 | 2009-12-31 | $2.41B | — | — |
| Q3 2009 | 2009-09-30 | $2.18B | $285.4M | +15.06% |
| Q2 2009 | 2009-06-30 | $2.21B | — | — |
| Q1 2009 | 2009-03-31 | $1.52B | — | — |
| Q3 2008 | 2008-09-30 | $1.90B | — | — |
Abbott Laboratories ebitda trends
Over the last five fiscal years, Abbott Laboratories's ebitda increased from $8.68B to $11.17B, a change of $2.48B. The latest reported quarter, Q1 2026, shows $2.15B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abbott Laboratories source filings ↗Community posts
Abbott launches blood-based colorectal cancer screening test in the US
Abbott ($ABT) has launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Freenome develops and manufactures the test, while Abbott holds exclusive commercialization ri ...
Abbott agrees to $385 million settlement over infant-formula recall claims
Abbott ($ABT) said it will pay $385 million to resolve a previously disclosed Justice Department investigation and lawsuit, together with claims brought by certain whistleblowers and state attorneys general. The matters concern manufacturin ...
